MBB Public Markets’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-209,271
Closed -$20.7M 555
2024
Q3
$20.7M Sell
209,271
-36,348
-15% -$3.57M 1.16% 27
2024
Q2
$22.8M Sell
245,619
-47,279
-16% -$4.24M 0.46% 41
2024
Q1
$27.8M Sell
292,898
-351,580
-55% -$32.6M 1.7% 18
2023
Q4
$57.5M Buy
644,478
+130,067
+25% +$9.66M 3.54% 9
2023
Q3
$37.6M Buy
514,411
+206,337
+67% +$16.5M 2.27% 11
2023
Q2
$25.6M Sell
308,074
-198,106
-39% -$16.6M 1.34% 21
2023
Q1
$38.6M Sell
506,180
-19,242
-4% -$1.6M 2.14% 12
2022
Q4
$43.6M Buy
525,422
+35,000
+7% +$2.83M 1.18% 12
2022
Q3
$38.9M Sell
490,422
-348,427
-42% -$29.4M 1.02% 11
2022
Q2
$62.3M Buy
838,849
+351,643
+72% +$26.4M 1.47% 6
2022
Q1
$43.8M Buy
487,206
+458,192
+1,579% +$42.3M 0.9% 8
2021
Q4
$3.25M Buy
+29,014
New +$3.5M 0.06% 46

Other funds holding XBI

MBB Public Markets's XBI Position: Q4 2024 in Review

MBB Public Markets sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 209,271 shares — an estimated $20.7M sold.

MBB Public Markets first reported a position in XBI in Q4 2021 and held it in 12 quarters. The position peaked at $62.3M in Q2 2022. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • MBB Public Markets reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • MBB Public Markets sold 209,271 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $20.7M.
  • MBB Public Markets first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 12 quarters.
  • MBB Public Markets's State Street SPDR S&P Biotech ETF position peaked at $62.3M in Q2 2022.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on MBB Public Markets's 13F filing for Q4 2024, filed 14 Feb 2025.